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Fas ligand drives insulitis in the non-obese diabetic mouse model of type 1 diabetes 
(T1D) and negatively regulates IL-10-producing (IL-10pos) CD5+ B  cells in pancreata. 
Relevance of these phenomena to the human disease is poorly understood. Here, using 
splenocytes from T1D, autoantibody (Ab+), and non-diabetic (ND) human subjects, we 
show that a subpopulation of CD5+ B cells that is characterized by expression of FasL 
(FasLhiCD5+) was significantly elevated in T1D subjects, many of whom had significantly 
reduced frequency of IL-10posCD5+ B cells compared to Ab+ subjects. The majority of 
FasLhiCD5+ B cells did not produce cytokines and were more highly resistant to activa-
tion-induced cell death than their IL-10posCD5+ counterparts. These results associate 
expansion of FasL-expressing CD5+ B cells with T1D and lay the groundwork for future 
mechanistic studies to understand specific role in disease pathogenesis.
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inTrODUcTiOn
Type 1 diabetes (T1D) results from the destruction of insulin-producing pancreatic β cells by 
diabetogenic T cells. Such diabetogenic T cells are held in check by an array of tolerogenic mecha-
nisms that maintain self-tolerance in the steady state (1). These mechanisms are mediated by a 
variety of immunoregulatory cell types and involve secretion of anti-inflammatory cytokines such 
as IL-10. In individuals at risk who progress to develop overt diabetes, regulatory mechanisms fail 
to curtail diabetogenic T cells that then attack and destroy β-cells, leading to hyperglycemia. This 
widely accepted model is built on extensive investigation of non-obese diabetic (NOD) mice and 
accumulated knowledge of the complex and often opposing roles of the immune cells in promoting 
and suppressing autoimmunity (2, 3). Whereas T cells are generally considered the main drivers 
of the diabetogenic process (4), B cells are equally important contributors. This is evident in the 
absence of significant insulitis and consequently overt hyperglycemia in B cell-deficient NOD mice 
(5–7). B cells are particularly important during the early inflammatory stage, including their role in 
enabling diabetogenic T cells to infiltrate pancreatic islets, resulting in the initiation and establish-
ment of insulitis. This role is primarily attributed to the potent capacity of B cells to capture and 
present islet autoantigens to autoreactive T cells (8), but increasing evidence suggests a more complex 
relationship (9, 10). Given the pivotal role of B cells in the disease process, dissecting the various 
mechanisms used by B cells to affect autoimmunity is thus important for understanding disease 
pathogenesis and developing effective B cell-directed therapy.
The immunoregulatory mechanisms, like the pathogenic ones, are predominated by T  cells 
and B  cells. Among T  cells, the Foxp3+ Treg cell, the best recognized immunoregulatory cell 
subtype, plays an essential role in maintaining insulitis in the benign state (11). Among B cells, 
there is no one definitive phenotype of the regulatory cells, but they are commonly enriched 
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within the CD5+ subpopulation (12). Functionally, regulatory 
B cells are collectively identified by production of IL-10 (13). 
Immunoregulatory cells encounter and at least temporarily 
regulate autoreactive T cells at two main checkpoints in NOD 
mice. These checkpoints were elegantly illustrated in NOD mice 
bearing a monoclonal population of islet-reactive BDC2.5 TCR 
transgenic T cells (14). The first checkpoint involves events in 
pancreatic lymph nodes where autoreactive T cells are primed 
and acquire effector functions as well as the ability to infiltrate 
and reside within pancreatic islets. Failures at this checkpoint 
are marked by the development of benign insulitis that becomes 
destructive when immunoregulatory mechanisms at the second 
checkpoint fail, leading to the loss of β-cells and ensuing hyper-
glycemia. Identification of the molecules that trigger the failure 
of immunoregulation is very important for devising strategies to 
prevent diabetes and to halt disease progression, and is actively 
being pursued.
One such trigger in mice is the apoptosis-inducing FasL 
ligand (FasL), which is necessary for insulitis development. 
This is revealed by the arrest of the disease at a preinsulitis 
stage in NOD mice bearing homozygous gld mutations of FasL 
(NOD-gld/gld) or lpr mutations of its Fas receptor (NOD-lpr/
lpr). This role of FasL is dominant as FasL-haploinsufficient 
NOD-gld/+ mice do not develop overt disease and only minor 
insulitis (15, 16). On the other hand, the primary physiological 
function of Fas/FasL interaction is induction of apoptosis of 
chronically activated lymphocytes and maintenance of immune 
homeostasis (17). Consequently, NOD-lpr/lpr and NOD-gld/
gld develop massive, age-dependent T cell lymphoproliferation, 
yet remain insulitis- and hyperglycemia-free (18). To reconcile 
these apparently contradictory findings, it was suggested that 
Fas/FasL interactions were also essential for β cell apoptosis. 
Subsequent studies, however, found that the Fas/FasL system 
is not essential for autoimmune destruction of β cells (19, 20), 
and mechanisms by which the Fas death pathway regulates 
T  cell islet infiltration remained obscured by the massive 
lymphoproliferation that develop in these mice. More recently, 
we and others have shown that the phenomena are dissociable 
as FasL haploinsufficiency (21) confers complete protection to 
NOD-gld/+ mice, which develop only minor insulitis but not 
lymphoproliferation (16, 22). Using these mice, we have shown 
that the gld mutation increases IL-10pos CD5+ B  cells in the 
pancreata and prevents insulitis by an IL-10-dependent mecha-
nism (23). Very little, however, if anything, is known about the 
cell types that carry pathogenic FasL and their relationship to 
IL-10pos CD5+ B cells. In addition, the relevance of these find-
ings to human T1D had remained largely unexplored, despite 
the potential of FasL as a therapeutic target as it is not directly 
involved in T cell activation, and its modulation does not cause 
generalized immunosuppression (24).
We began addressing these questions in the present study. 
Our results associate expansion of FasL-expressing B cells with 
autoimmune diabetes and implicate them in the deletion of 
IL-10-producing Breg cells. The results suggest relevance of the 
long-known role of FasL in regulating susceptibility of NOD 
mice to autoimmune diabetes to the human disease and lay the 
groundwork for future mechanistic studies.
MaTerials anD MeThODs
human Donors and Tissue Procurement
Splenocytes used in this study were procured, recovered, and 
processed by the Network for Pancreatic Organ Donors with 
Diabetes (nPOD) and delivered in cryovials in liquid nitrogen 
and then kept at −80°C in our laboratory until used. Samples 
were from three cohorts: 14 T1D, 8 diabetes-free subjects with 
T1D-associated autoantibodies (Ab+), and 10 non-diabetic (ND) 
subjects. Clinical characteristics of donors are shown in Table 1.
Processing and analysis strategy 
of human samples
To minimize any effect of inter-experimental variation and main-
tain consistency of gating used to identify positive subpopula-
tions in different diabetic, Ab+, and ND subjects, we performed 
our analysis by matching one T1D sample with at least one Ab+ 
and/or ND sample in each experiment, and the latter were used 
to draw gates to reduce any bias that could have resulted from 
analyzing T1D separately from Ab+ and ND samples. In total, we 
collected and performed statistical analysis in data pooled from 
10 to 14 independent experiments. In each experiment, frozen 
splenocytes were thawed by using a standard operating procedure 
provided by nPOD. Briefly, cryovials were removed from liquid 
nitrogen, rapidly thawed with vigorous shaking for 2–3 min in 
a 37°C water bath, and added to pre-warmed medium (RPMI+ 
10% FBS+ 50 U/mL Benzonase). Cells were centrifuged, washed, 
and counted by using trypan blue, and 1 × 106 cells were used 
per application, unless stated otherwise. The absence of informa-
tion regarding the absolute numbers of lymphocytes per spleen 
(we also received small pieces) made determination of absolute 
numbers of each subset per subject just a mere reflection of 
their frequency among acquired events, and for this reason we 
presented the data only as frequency of their indicated subsets.
staining reagents
Fluorochrome-conjugated monoclonal antibodies (mAbs) spe-
cific for human antigens were obtained, unless stated otherwise, 
from BD Pharmingen (San Jose, CA, USA), BioLegend (San 
Diego, CA, USA), or eBioscience (San Diego, CA, USA). The 
following anti-human mAbs (clone) were used: FasL (NOK-1), 
Fas (DX2), CD19 (H1B19), CD5 (L17F12), CD40 (5C3), CD86 
(IT2.2), CD20 (2H7), CD27 (LG.7F9), CD38 (HIT2), CD22 450 
(S-HCL-1), CD10 (HI10a), CD1d (51.1), IL-10 (JES3-9D7), active 
caspase 3 (C92-605), IL-17 (eBio64DEC17), and IFN-γ (B27). 
Surface expression of human FasL was analyzed by using biotin-
conjugated NOK-1 mAb. Previously described (25, 26) humanized 
anti-human FasL (RNOK203) was provided by Dr. Hideo Yagita of 
Juntendo University and Dr. Toshihiro Maeda of The Chemo-Sero 
Therapeutic Research Institute (Kaketsuken) in Japan.
Facs analysis of surface Markers and 
intracellular cytokines
Single cell suspensions were stained with predetermined optimal 
concentrations of indicated mAbs. Samples were then washed 
and acquired using FACS LSRII flow cytometer and analyzed by 
TaBle 1 | clinical and demographic details of donors provided by network for Pancreatic Organ Donors with Diabetes.
id status autoantibody age Duration gender c peptide (ng/ml) hb1ac BMi
6180 T1D GADA+ IA-2A+ ZnT8A+ mIAA+ 27.1 11 M <0.05 UK 25.9
6128 T1D mIAA+ 33.8 31.5 F <0.05 UK 22.2
6138 T1D mIAA+ 49.2 41 F <0.05 UK 33.7
6224 T1D Neg 21 1.5 F <0.05 UK 22.8
6152 T1D ZnT8A(+) 29.6 12 F <0.05 11.3 30.1
6204 T1D GADA+ mIAA+ 28 21 M 0.05 7.2 23.08
6211 T1D GADA+ IA-2A+ ZnT8A+ mIAA+ 24 4 F 0.05 10.5 24.4
6212 T1D mIAA+ 20 5 M 0.05 6.4 29.1
6236 T1D GADA+ mIAA+ 25 14 M 0.05 11.6 20.1
6237 T1D GADA+ mIAA+ 18 12 F 0.05 UK 26
6241 T1D mIAA+ 33 31 M 0.05 UK 18.4
6242 T1D IA-2A+ mIAA+ 39 19 M 0.05 UK 19.5
6244 T1D mIAA+ 34 28 M 0.05 5.9 23.8
6195 T1D GADA+ IA-2A+ ZnT8A+ mIAA+ 19.2 5 M 0.05 23.7
6170 Ab+ GADA+ 34.4 NA F 4.29 6.9 36.9
6123 Ab+ GADA+ 23.2 NA F 2.01 5.4 17.6
6158 Ab+ GADA+ mIAA+ 40.3 NA M 0.51 5.6 29.7
6184 Ab+ GADA+ 47.5 NA F 3.42 UK 27
6151 Ab+ GADA+ 30 NA M 5.49 UK 24.2
6156 Ab+ GADA+ 40 NA M 13.34 UK 19.9
6181 Ab+ GADA+ 31.9 NA M 0.61 UK 21.9
6171 Ab+ GADA+ 4.3 NA F 8.95 UK 14.8
6179 ND Neg 21.8 NA F 2.74 UK 20.7
6160 ND Neg 22.1 NA M 0.4 5.2 23.9
6131 ND Neg 24.2 NA M 1.01 UK 24.8
6140 ND Neg 38 NA M 11.1 6 21.7
6172 ND Neg 19.2 NA F 8.02 5.4 32.4
6165 ND Neg 46 NA F 4.45 UK 25
6229 ND Neg 31 NA F 6.23 5.5 26.9
6234 ND Neg 20 NA F 6.89 5.8 25.6
6174 ND Neg 20.8 NA M 3 UK 19.5
6178 ND Neg 25 NA F 4.55 UK 27.5
T1D, type 1 diabetes; Ab+, autoantibody positive without diabetes; ND, non-diabetic and no autoantibody donors; UK, unknown; IA-2A, islet antigen-2 antibody; GADA, glutamic 
acid decarboxylase antibody; ZnT8A, zinc transporter 8 autoantibody; mIAA, microinsulin autoantibody.
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Flow-JOV10 software. Three types of specificity controls were 
used. First, compensations were properly set using single-stained 
samples. Second, Fluorescence-Minus-One unstained samples 
and those stained with isotype controls were used to specifically 
gate positive cells and set up quadrants. Third, comparison of 
positive and negative cells in samples from donors (T1D, Ab+, 
and ND), and when appropriate, stimulated vs unstimulated sam-
ples provided internal controls. For intracellular staining, single 
cell suspensions were stimulated for 6 h with phorbol myristate 
acetate (PMA) (50 ng/mL) and ionomycin (500 ng/mL) in the 
presence of Golgi-Plug (2 mmol/L). Surface staining was followed 
by cell fixation, permeabilization, and intracellular staining with 
anti-IL-10, IL-17, TNFα, or IFN-γ mAb as indicated.
caspase 3 apoptosis assay
Splenocytes were stimulated with 10  µg/mL of affinity 
purified polyclonal goat F(ab’)2 anti-human IgM (Jackson 
ImmunoResearch) for 24 h at 37°C in the presence or absence 
of humanized anti-human FasL-neutralizing mAb (RNOK203) 
or the general caspase inhibitor Z-VAD-FMK (BD Biosciences). 
During the last 6 h of incubation, cultures were stimulated with 
PMA and ionomycin in the presence of Golgi-Plug, followed by 
surface staining and intracellular detection of IL-10 and active 
caspase 3 using specific mAbs. It is noteworthy that number of 
cells obtained per sample was limiting and did not allow a more 
direct and extensive analysis such as multi-color FACS analysis 
for FasL, Fas, CD5 on B cells without culture with anti-FasL mAb. 
Such analysis would have directly addressed whether IL-10-
producing CD5+ B cells are specifically targeted for apoptosis.
statistical analysis
Unless otherwise indicated, all data are shown as mean ± SEM. 
Statistical analysis was performed using the unpaired Mann–
Whitney U test. A two-tailed value of p ≤ 0.05 was considered 
statistically significant. Statistical analysis and graph preparation 
were performed by using GraphPad Prism software (GraphPad 
Software, Inc., La Jolla, CA, USA).
resUlTs
Detection of il-10- and Fasl-expressing 
cD5+ B subpopulations That are 
selectively altered in ab+ and T1D 
subjects
It has long been known that FasL regulates insulitis and autoim-
mune diabetes development in NOD mice. In addition, our recent 
data showed that genetic or antibody inactivation of FasL leads 
FigUre 1 | il-10pos cD5+, but not il-10pos cD5− B cells, are selectively enriched in ab+ as compared to type 1 diabetes (T1D) and nD subjects. 
Cryopreserved splenocytes from T1D, Ab+, and ND subjects were thawed and stimulated with phorbol myristate acetate and ionomycin, stained, and indicated 
subsets were gated as described under Section “Materials and Methods” and analyzed for IL-10 expression. (a) Left, dot plot shows gating strategy of CD5+ and 
CD5− subsets of CD19+ B cells and CD5+ CD19− T cells. Right, representative dot plots show intracellular expression of IL-10 by gated CD5+ and CD5− B cells and 
T cells in different subjects. (B) Graphs show cumulative data pooled from 11 independent experiments. In each experiment, one T1D subject is paired with Ab+ 
and/or an ND subject. Each symbol represents a subject. Data were analyzed using the Mann–Whitney test and expressed as mean ± SEM; p < 0.05 is statistically 
significant.
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to significant increases in IL-10-producing CD5+ B  cells in the 
pancreata (23). To investigate relevance of these findings to the 
human disease, we analyzed IL-10- and FasL-expressing B and 
T cells in splenocytes from T1D, Ab+, and ND subjects. Overview  
of the gating strategy used to identify lymphocytes, exclude 
doublets and dead cells is outlined (Figure S1 in Supplementary 
Material). B cells are often analyzed as one population, yet they 
are heterogeneous and contain CD5+ B  cells that are viewed 
as autoreactive and expanded in T1D patients [Figure S2 in 
Supplementary Material; Ref (27–30)]. CD5+ B cells also harbor 
the IL-10-producing regulatory subset. We therefore analyzed 
them separately from the CD5− B cell subpopulation. CD5 is oth-
erwise a pan marker of T cells. We stimulated samples with PMA/
ionomycin and used the depicted gating strategy (Figure 1A) to 
distinguish between CD5+ CD19+ and CD5− CD19+ B cells and 
CD5+ CD19− T cells. Each subset was analyzed for IL-10 produc-
tion in various subjects. Our results show that the frequency of 
IL-10pos CD5+ B cells was significantly higher in Ab+ as compared to 
T1D subjects (Figures 1A,B). The difference was also significant 
when examined at the level of the absolute numbers of IL-10pos 
CD5+ B cells (Figure S3 in Supplementary Material). On the other 
hand, the frequency, but not the absolute numbers, of IL-10pos 
CD5+ B  cells was higher in the Ab+ subjects than ND subjects 
(Figure S3 in Supplementary Material). There were no signifi-
cant differences, however, in the frequency of IL-10-expressing 
CD5− B  cells (IL-10pos CD5− B  cells) among the subjects in the 
three groups, excluding generalized upregulation of IL-10 in 
B cells of Ab+ subjects. Consequently and in line with the fact that 
FigUre 2 | Faslhi cD5+, but not of Faslhi cD5– B cells, are selectively enriched in type 1 diabetes (T1D) as compared to ab+ and nD subjects. 
Cryopreserved splenocytes from T1D, Ab+, and ND subjects were thawed and surface-stained, and indicated subsets identified as described in Figure 1a were 
gated and analyzed for surface expression of FasL. (a) Representative dot plots show FasL expression by gated CD5+ and CD5− B cells and T cells in different 
subjects. (B) Graphs show cumulative data pooled from at least 14 independent experiments. In each experiment, one T1D subject is paired with Ab+ and/or an ND 
subject. Each symbol represents one subject. Data were analyzed using the Mann–Whitney test and expressed as mean ± SEM; p < 0.05 is statistically significant.
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CD5− B cells comprised the bulk of B cells, the overall frequency of 
IL-10-expressing cells among total B cells (IL-10pos B cells) was not 
statistically different among subjects in the three groups (Figure 
S4 in Supplementary Material). The frequency of IL-10pos T cells, 
however, was significantly less in T1D as compared to ND, but 
not Ab+ subjects (Figure 1B). We concluded that there is selective 
expansion of IL-10pos CD5+ B cells in Ab+ as compared to T1D sub-
jects. The results extend the idea that the regulatory mechanisms 
in at-risk individuals, unlike in T1D progressors, are augmented 
and actively working to control islet autoreactivity (31, 32).
FigUre 3 | Most Faslhi cD5+ B cells do not produce il-10 and exhibit less antigen-experience than il-10pos cD5+ B cells. Cryopreserved splenocytes 
from type 1 diabetes (T1D), Ab+, and ND subjects were thawed and cultured in the presence or absence of phorbol myristate acetate and ionomycin for 6 h and 
analyzed simultaneously for surface expression of FasL and intracellular IL-10 as described under Section “Materials and Methods.” (a) Representative dot plots 
show expression of IL-10 and FasL by gated CD5+ B cells among stimulated and unstimulated cultures from T1D, Ab+, and ND subjects. Of note, the T1D dot plot 
was from the donor with the highest level of IL-10 expression so that the differential expression of FasL and IL-10 is better seen. (B) Graph shows expression of 
indicated surface molecules on gated IL-10pos and FasLhi subpopulations of CD5+ cells from stimulated cultures. Data are pooled from two independent experiments 
and four individually analyzed T1D subjects. Data were analyzed using the Mann–Whitney test and expressed as mean ± SEM; p < 0.05 is statistically significant.
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Next, we determined whether FasL expression is dysregulated 
in B or T cells in any of the three subject groups. We detected sig-
nificant differences that, as above, were limited to the CD5+ B cell 
subpopulation, albeit in the opposite direction, as the frequency 
of FasL-expressing CD5+ B  cells (FasLhi CD5+) was significantly 
higher in T1D as compared to Ab+ and ND subjects (Figure 2A). 
The frequency of FasL-expressing CD5− B cells (FasLhi CD5−) was 
generally low and slightly higher in T1D, but the difference among 
the groups did not reach statistical significance (Figure  2B). 
Likewise, the frequency of FasL-expressing T cells was comparable 
in the three groups, thereby excluding a generally dysregulated 
expression of FasL in T1D subjects (Figure 2B). In addition, CD5+ 
B  cells in T1D, Ab+, and ND subjects had comparable surface 
expression of CD86 and CD40, confirming that the detected 
changes in IL-10 and FasL expression by these cells was specific and 
not due to generalized modulation of their surface profile (Figure 
S5 in Supplementary Material). Taken together, our results show 
IL-10pos CD5+ B cells are selectively expanded in Ab+ subjects as 
opposed to selective expansion of FasLhi CD5+ B cells T1D subjects.
Faslhi cells Do not Produce cytokines 
and have reduced susceptibility to 
activation-induced cell Death (aicD)
The differential expansion of FasLhi and IL-10pos CD5+ cells in 
Ab+ and T1D indicated that they might represent two separate 
subpopulations. To directly test this notion, we simultaneously 
analyzed FasL and IL-10 expression at the single cell level in 
the CD5+ B  cells from T1D, Ab+, and ND subjects by FACS 
after rapid PMA/ionomycin stimulation to upregulate IL-10. As 
predicted, we detected two distinct subpopulations that express 
either IL-10 or FasL in three types of donors (Figure  3A). 
The distinction, however, was not absolute as some cells were 
dual positive for FasL and IL-10. Nonetheless, the inability of 
FasL-expressing cells to produce cytokines was not limited to 
IL-10 or CD5+ B cells as it was the case with IFN-γ, TNFα, and 
IL-17 and for CD5− B cells and T cells (Figure 3A; Figure S6 in 
Supplementary Material). Whether FasLhi CD5+ B cells secrete 
cytokines other than those examined here cannot be formally 
ruled out and await to be determined. Differences between 
IL-10pos and FasLhi CD5+ cells extend to activation markers. 
IL-10pos CD5+ B  cells expressed significantly higher levels of 
CD1d and CD27 and lower levels of CD10 and CD22 than FasLhi 
CD5+ B  cells; but both expressed comparable levels of CD38 
(Figure 3B; Figure S7 in Supplementary Material).
FasLhi CD5+ B  cells expressed less Fas and were less sus-
ceptible to AICD than FasLneg CD5+ B cells, including IL-10pos 
CD5+ B cells. This was examined by the analysis of intracellular 
levels of active caspase 3 in anti-IgM-stimulated cultures. In 
this experiment, we stimulated splenic cultures with anti-IgM 
for 24 h and analyzed gated FasLhi and FasLneg subpopulations 
of CD5+ B cells for AICD. Most of apoptotic cells belonged to 
FigUre 4 | resistance of Faslpos cD5+ B cells to activation-induced cell death. (a) Cryopreserved splenocytes from type 1 diabetes (T1D) donors were 
thawed and stimulated with anti-IgM at 37°C for 24 h and analyzed for expression of active caspase 3 and FasL as detailed under Section “Materials and Methods.” 
Left, representative dot plot shows expression of active caspase 3 and FasL by gated CD5+ B cells. Right, graph shows cumulative data of frequency of caspase 3+ 
cells among gated FasLpos and FasLneg subpopulations of CD5+ B cells. Symbols represent individual donors. Data are expressed as mean ± SEM; p < 0.05 is 
statistically significant. (B) Percentage and levels (MFI) of Fas expression are significantly higher in IL-10+ CD5+ B cells in T1D than in Ab+ and ND subjects. 
Splenocytes from indicated donors were rapidly stimulated with phorbol myristate acetate/ionomycin and analyzed for intracellular IL-10 and Fas surface expression 
as described under Section “Materials and Methods.” Left, representative dot plot shows expression of IL-10 and Fas by gated CD5+ cells. Right, graphs show 
percentage (left) and mean fluorescent intensity (MFI) of Fas (right) on IL-10+ CD5+ B cells in subjects from the three groups. Data are expressed as mean ± SEM; 
p > 0.05 is statistically significant. (c) Cryopreserved splenocytes from T1D subjects were thawed and stimulated at 37°C with anti-IgM in the presence of 
FasL-neutralizing (RNOK203), the global apoptosis inhibitor, ZVAD, or in medium alone. After 24 h, cells in each culture were stained, and gated CD5+ B cells were 
analyzed for expression of active caspase 3 and IL-10. Left, dot plots show representative expression of active caspase 3 and IL-10 on gated CD5+ B cells under 
the different culture conditions. Right, graph shows cumulative data of percentage of IL-10+ CD5+ B cells that expressed active caspase 3 under each condition. 
Each symbol represents a subject (n = 5). Data was analyzed using Wilcoxon Matched pair sign rank test. Data are expressed as mean ± SEM; p < 0.05 is 
statistically significant.
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the FasLneg subpopulation (Figure  4A) in which IL-10pos cells 
resided. Therefore, in a second set of experiments, we examined 
whether AICD of IL-10pos CD5+ cells was mediated by the 
Fas pathway. Consistent with this result, there was high Fas 
expression on IL-10pos CD5+ B  cells (Figure  4B, plot), which 
often denote sensitivity to AICD (33). The frequency of IL-10pos 
CD5+ cells was significantly higher in T1D than in Ab+ and ND 
subjects (Figure 4B, graphs). On the other hand, mean level of 
Fas expression (MFI) was higher in T1D but was not statisti-
cally different than its levels in Ab+ and ND subjects. Moreover, 
apoptosis of IL-10pos cells was inhibited by FasL-neutralizing 
mAb to an extent that was comparable to that induced by the 
pan caspase inhibitor, ZVAD (Figure 4C). It is noteworthy that 
cultures treated with anti-FasL mAb often reduced the overall 
frequency of IL-10-producing B cells, suggesting perhaps a role 
for FasL in regulating IL-10 production that is worthy of future 
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investigation. Taken together, these results show that most FasLhi 
CD5+ B cells did not produce any of examined cytokines and that 
they differed from IL-10pos CD5+ B cells in their activation state 
and susceptibility to AICD.
In summary, our results extend the long-known role for FasL in 
regulating pathogenesis of autoimmune diabetes in NOD mice to 
the human disease by showing dysregulated homeostasis of FasLhi 
CD5+ B cells in T1D subjects. Future studies using conditional 
knock mice that lack FasL only in B cells will determine whether 
FasL expression in B cells plays an essential role in driving the 
diabetic process.
DiscUssiOn
The present study associates a subpopulation of B  cells that is 
characterized by the expression of FasL and CD5 (FasLhi CD5+ 
B  cells) with autoimmune diabetes in humans. Furthermore, 
our finding that T1D subjects harbor significantly fewer IL-10pos 
CD5+ B cells than Ab+ subjects (Figure 4) confirms and offers 
plausible explanation for the recent observations by Kleffel et al. 
(34) and Deng et al. (35) of decreased frequency of IL-10pos Breg 
cells in T1D. We speculate that FasL+ CD5+ B  cells could be 
involved in the deletion of IL-10pos CD5+ B cells. This notion is 
consistent with our previous findings that genetic inactivation of 
FasL in NOD mice increases the frequency of pancreatic IL-10pos 
B cells and prevents insulitis development by an IL-10-dependent 
mechanism (23). Furthermore, paucity of IL-10pos CD5+ B cells 
in NOD-wt mice is rapidly reversed by antibody blockade of 
FasL (23). The results begin to show relevance of the well-known 
pathogenic roles of functional Fas/FasL interactions in driving 
autoimmune diabetes in the NOD mouse model to human T1D. 
The results lay the foundation for developing strategies that target 
FasL for therapeutic purpose.
Historically, investigation of Fas-mediated apoptosis has 
been focused on T  cells (36). Thus, identifying B  cells as a 
critical source of pathogenic FasL appeared surprising. However, 
Fas-mediated apoptosis is a well-established deletion mechanism 
of autoreactive B cells (37, 38). Breakdown in this tolerance mech-
anism causes generalized expansion of B cells and production of 
autoantibodies in mice bearing homozygous loss-of-function gld 
or lpr mutations (39). Moreover, conditional deletion of Fas in 
B cells allows autoreactive B cells to escape checkpoints and qual-
ity control mechanisms in germinal centers (37, 38). Expansion 
of IL-10pos CD5+ B cells in NOD-gld/+ mice or after injection of 
NOD-wt mice with FasL-neutralizing mAb suggests a direct role 
of Fas-mediated apoptosis in regulation of IL-10pos CD5+ B cell 
homeostasis (23). In relevance to the human disease, our present 
results show that IL-10pos CD5+ B cells in T1D subjects expressed 
significantly higher levels of Fas than in Ab+ and ND subjects, 
hence enhanced susceptibility to apoptosis (Figure 4B). We also 
must acknowledge that our data are indirect, and hopefully future 
experiments will assess this possibly directly at the single cell level.
It is clear that both FasLhi CD5+ B  cells and IL-10pos CD5+ 
B cells have tinges of autoreactivity that could be subjecting them 
to Fas-mediated regulation. A primary indicator is the expres-
sion of CD5, which is usually associated with high self-reactivity, 
not only in B cells but also in T cells (40). Furthermore, FasLhi 
CD5+ B cells and IL-10pos CD5+ B cells were the only B cell sub-
populations that were modulated up and down in manners that 
correlated with islet autoimmunity in both humans and mice. 
In contrast, there were no appreciable changes in frequencies of 
FasLhi or IL-10pos CD5− B cells (Figures 1 and 2). IL-10pos CD5+ 
B cells also expressed high levels of CD27 and CD1d (Figure 3B). 
CD27 is a general marker of memory B  cells (41), and CD27+ 
B cells are more susceptible to apoptosis than CD27− B cells in 
common variable immunodeficiency (42) and lupus patients 
(43). In addition, high expression of CD1d fits well with our 
characterization of IL-10pos CD5+ subpopulation as regulatory 
B cells (12). In contrast, FasLhi CD5+ B cells expressed high level of 
CD22 (Figure 3B). CD22 is a negative regulator of BCR signaling 
that diminishes B cell activation, and CD22-sufficient B cells are 
shown to be more resistant to anti-IgM-induced apoptosis than 
CD22-deficient B cells (44). Thus, phenotypic profiles of IL-10pos 
CD5+ B cells and FasLhi CD5+ B cells support the premise of this 
study that IL-10pos CD5+ B  cells are more antigen-experienced 
and likely more prone to Fas-mediated apoptosis than their FasLhi 
CD5+ B counterparts.
In summary, the elevated frequency of FasLhi CD5+ B cells in 
T1D subjects extends our previous findings to the human disease 
and begins to shed new light into a previously unappreciated 
dysregulation of the Fas pathway in T1D subjects.
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